首页
订购/客服:400-666-5481

Rogaratinib

    
≥98%

4-((4-amino-5-(7-methoxy-5-methylbenzo[b]thiophen-2-yl)-6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methyl)piperazin-2-one

源叶(MedMol)
S87691 一键复制产品信息
1443530-05-9
C₂₃H₂₆N₆O₃S
466.56
Rogaratinib; BAY-1163877: BAY1163877: BAY 1163877
货号 规格 价格 上海 北京 武汉 南京 购买数量
S87691-2mg
≥98% ¥1500.00 货期:2-3天 - - -
S87691-5mg
≥98% ¥2000.00 货期:2-3天 - - -
S87691-10mg
≥98% ¥3200.00 货期:2-3天 - - -
S87691-25mg
≥98% ¥4800.00 货期:2-3天 - - -
S87691-100mg
≥98% ¥12800.00 货期:2-3天 - - -
产品介绍 参考文献 质检证书(COA) 摩尔浓度计算器 相关产品

产品介绍

Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor.

产品描述: Rogaratinib (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor.
靶点: FGFR1;FGFR2;FGFR3;FGFR4
体外研究: Of the 24 cell lines, 2 FGFR1-amplified lung cancer (LC) cell lines, H1581 and DMS114, show extreme sensitivity to Rogaratinib (BAY1163877) (GI50 values ranging from 36 to 244 nM). Treatment with Rogaratinib results in a significant decrease in colonies formed by H1581P cells, but not by H1581AR and BR cells. Ectopic expression of Met significantly induces resistance to Rogaratinib in MTT assays. Met overexpression induces activation of downstream extracellular signal-regulated kinase 1/2 (ERK1/2) and AKT, which cannot be abrogated by Rogaratinib treatment.
参考文献: 1. Kim SM, et al. Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy. Oncogenesis. 2016 Jul 18;5(7):e241.
溶解性: Soluble  in  DMSO
保存条件: -20°C
配置溶液浓度参考:
1mg 5mg 10mg
1 mM 2.143 ml 10.717 ml 21.433 ml
5 mM 0.429 ml 2.143 ml 4.287 ml
10 mM 0.214 ml 1.072 ml 2.143 ml
50 mM 0.043 ml 0.214 ml 0.429 ml
注意: 部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。

参考文献

质检证书(COA)

如何获取质检证书(COA)?
请输入货号和一个与之匹配的批号。
例如:
批号:JS298415 货号:S20001-25g
在货品标签上如何找到货号和批号?

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

=
×
×